JP2023545229A5 - - Google Patents
Info
- Publication number
- JP2023545229A5 JP2023545229A5 JP2022573176A JP2022573176A JP2023545229A5 JP 2023545229 A5 JP2023545229 A5 JP 2023545229A5 JP 2022573176 A JP2022573176 A JP 2022573176A JP 2022573176 A JP2022573176 A JP 2022573176A JP 2023545229 A5 JP2023545229 A5 JP 2023545229A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2016463.8A GB202016463D0 (en) | 2020-10-16 | 2020-10-16 | Product |
| GB2016463.8 | 2020-10-16 | ||
| GBGB2104148.8A GB202104148D0 (en) | 2021-03-24 | 2021-03-24 | Product |
| GB2104148.8 | 2021-03-24 | ||
| PCT/GB2021/052689 WO2022079453A1 (en) | 2020-10-16 | 2021-10-18 | Nucleic acid encoding an anti-vegf entity and a negative complement regulator and uses thereof for the treatment of age-related macular degeneration |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023545229A JP2023545229A (ja) | 2023-10-27 |
| JP2023545229A5 true JP2023545229A5 (https=) | 2024-10-28 |
| JPWO2022079453A5 JPWO2022079453A5 (https=) | 2024-10-28 |
Family
ID=78463555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573176A Pending JP2023545229A (ja) | 2020-10-16 | 2021-10-18 | 抗ｖｅｇｆ実体および負の補体調節因子をコードする核酸、ならびに加齢黄斑変性の処置のためのその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230212275A1 (https=) |
| EP (1) | EP4229076A1 (https=) |
| JP (1) | JP2023545229A (https=) |
| KR (1) | KR20230088630A (https=) |
| CN (1) | CN119585299A (https=) |
| AU (1) | AU2021362770A1 (https=) |
| CA (1) | CA3182337A1 (https=) |
| CL (1) | CL2023001072A1 (https=) |
| CO (1) | CO2023005981A2 (https=) |
| CR (1) | CR20230202A (https=) |
| DO (1) | DOP2023000076A (https=) |
| EC (1) | ECSP23034907A (https=) |
| IL (1) | IL298527A (https=) |
| JO (1) | JOP20230076A1 (https=) |
| MX (1) | MX2023004377A (https=) |
| PE (1) | PE20231747A1 (https=) |
| PH (1) | PH12023551015A1 (https=) |
| WO (1) | WO2022079453A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| GB201821089D0 (en) | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Codon-optimised complement factor I |
| JP7842082B2 (ja) * | 2020-07-21 | 2026-04-07 | エフティージェン コーポレーション | 眼疾患を処置するための組成物および方法 |
| WO2025083169A1 (en) * | 2023-10-17 | 2025-04-24 | Tenpoint Therapeutics Limited | Combination of a vegf inhibitor and a complement pathway inhibitor for treating ocular disorders |
| KR20260004635A (ko) * | 2024-07-01 | 2026-01-09 | 삼성바이오에피스 주식회사 | 애플리버셉트를 암호화하는 코돈-최적화된 폴리뉴클레오티드를 포함하는 발현 카세트 및 이를 포함하는 rAAV 생산용 플라스미드 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2191001T3 (en) | 2007-04-09 | 2016-09-19 | Univ Florida | RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF |
| BR112014013205A2 (pt) * | 2011-12-01 | 2020-10-27 | Protevobio, Inc. | proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit |
| JP7046828B2 (ja) * | 2016-04-15 | 2022-04-04 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 滲出型加齢性黄斑変性の治療のための組成物 |
| AU2018350990A1 (en) * | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap |
| CN111788311A (zh) * | 2017-10-20 | 2020-10-16 | 双子治疗公司 | 用于治疗年龄相关性黄斑变性的组合物和方法 |
| US12558434B2 (en) | 2018-02-20 | 2026-02-24 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| GB201821089D0 (en) * | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Codon-optimised complement factor I |
| GB201821082D0 (en) * | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Combination of complement factors i and h, and vector encoding thereof |
| EP4048318A4 (en) * | 2019-10-23 | 2023-11-22 | Gemini Therapeutics Sub, Inc. | METHOD FOR TREATING PATIENTS WITH CFH MUTATIONS USING RECOMBINANT CFH PROTEINS |
-
2021
- 2021-10-18 MX MX2023004377A patent/MX2023004377A/es unknown
- 2021-10-18 CR CR20230202A patent/CR20230202A/es unknown
- 2021-10-18 CA CA3182337A patent/CA3182337A1/en active Pending
- 2021-10-18 KR KR1020227041935A patent/KR20230088630A/ko active Pending
- 2021-10-18 CN CN202180039494.2A patent/CN119585299A/zh active Pending
- 2021-10-18 AU AU2021362770A patent/AU2021362770A1/en active Pending
- 2021-10-18 US US17/928,803 patent/US20230212275A1/en active Pending
- 2021-10-18 WO PCT/GB2021/052689 patent/WO2022079453A1/en not_active Ceased
- 2021-10-18 EP EP21801205.2A patent/EP4229076A1/en active Pending
- 2021-10-18 JP JP2022573176A patent/JP2023545229A/ja active Pending
- 2021-10-18 IL IL298527A patent/IL298527A/en unknown
- 2021-10-18 PE PE2023001418A patent/PE20231747A1/es unknown
- 2021-10-18 PH PH1/2023/551015A patent/PH12023551015A1/en unknown
-
2023
- 2023-04-14 DO DO2023000076A patent/DOP2023000076A/es unknown
- 2023-04-14 CL CL2023001072A patent/CL2023001072A1/es unknown
- 2023-04-16 JO JOJO/P/2023/0076A patent/JOP20230076A1/ar unknown
- 2023-05-10 CO CONC2023/0005981A patent/CO2023005981A2/es unknown
- 2023-05-11 EC ECSENADI202334907A patent/ECSP23034907A/es unknown